Context: Glucocorticoids increase the risk of nonvertebral fracture, but no clinical trial has shown that nonvertebral fractures can be prevented by coadministration of an antiosteoporotic drug.
A s glucocorticoids are potent anti-inflammatory and immunosuppressive drugs, they are used by an estimated 1% to 3% of some countries' general population (1) (2) (3) . Unfortunately, these drugs are considered to be the leading cause of secondary osteoporosis (4) . This side effect is best documented for oral glucocorticoids, which have been associated with decreased bone mineral density after only 3 months of therapy (5) . At doses $2.5 mg/d (prednisolone or equivalent), oral glucocorticoids have been associated with an increased risk of both vertebral and nonvertebral fractures (6) . The highest risk of fracture is seen in older adults (6) .
To prevent fractures, glucocorticoids may be coadministered with drugs for osteoporosis. The most widely used drug for osteoporosis is alendronate, a bisphosphonate (7) . In clinical trials, coadministration of alendronate has shown beneficial effects on bone mineral density (8) . Bone mineral density is an imperfect surrogate outcome of fracture (9) , but neither clinical trials of alendronate nor those of other bisphosphonates have been powered to demonstrate reductions in fractures among patients taking glucocorticoids (10, 11) . Although a few of these trials still demonstrated substantial reductions in vertebral fractures, they did not demonstrate relevant reductions in nonvertebral fractures (8, 12) . Also, in meta-analyses, substantial reductions in nonvertebral fractures have not been observed (10, 11) . Therefore, we conducted a nationwide retrospective cohort study to estimate the effect of alendronate on the risk of nonvertebral fracture in older adults taking oral glucocorticoids ($2.5 mg/d of prednisone or equivalent for $3 months).
Materials and Methods

Data sources
The data for this study were obtained from three databases owned by the Swedish government. First, the Prescribed Drug Register provided data on prescription drugs dispensed in Sweden since July 2005 (13) . Second, the National Patient Register provided data on medical conditions diagnosed in any hospitalized care in Sweden since 1987 and any ambulatory specialist care since 2001 (14) . Third, the Cause of Death Register provided data on deaths. In the current study, we had access to data for a closed cohort that comprised every resident of Sweden who was aged $50 years on 31 December 2005. The datasets we received had been deidentified by Statistics Sweden. Ethics approvals were obtained from Statistics Sweden, the National Board of Health and Welfare, and the Regional Ethical Review Board in Umeå. These institutions did not require us to obtain informed consent.
Inclusion criteria
We included subjects who initiated oral glucocorticoid therapy from 2006 through 2011, which we defined as being dispensed a glucocorticoid during this period but not from July through December 2005 (a 6-month period). We required subjects to receive $2.5 mg/d of prednisone (or equivalent) for $91 days. Prednisone-equivalent doses were computed using the relative potencies available in Supplemental Table 1 . We excluded subjects who were dispensed a bisphosphonate (alendronate, risedronate, or zoledronic acid) prior to being dispensed a glucocorticoid or from July through December 2005. Drug dispensations were identified using Anatomical Therapeutic Chemical codes recorded in the Prescribed Drug Register (Supplemental Table 2 ).
The duration of glucocorticoid therapy was defined as the time span between the first and final dispensations plus 90 days. Thus, at least two dispensations were required. We estimated the average daily dose by any given date in two steps. First, the total dispensed dose by a given date was summed. Second, this quantity was divided by the number of days from the first dispensation to the dispensation following the given date (or to 90 days after the final dispensation). Thus, we assumed that all of the glucocorticoids a patient had been dispensed by a given date were consumed by the time of the next dispensation. This estimate of average daily dose enabled it to vary over time, as is common in glucocorticoid therapy (15) .
Matching
We matched subjects one-to-one using time-dependent propensity scores, a method that enables matching on timevarying exposures (such as alendronate use) and confounders (16) . In brief, we matched the first subject who received alendronate after initiating glucocorticoid therapy to a subject who either never received alendronate or later received alendronate. Then, this matched pair was set aside, and the procedure was repeated for the next of the remaining subjects who received alendronate. This procedure continued until no more pairs could be matched. The rationale for allowing subjects who later received alendronate to be matched as nonusers is to reduce confounding, as later-treated and earlier-treated subjects may be more comparable than ever-treated and nevertreated subjects (17) .
The matched sample was constructed using a nearestneighbor algorithm (Psmatch2 command in Stata; StataCorp, College Station, TX). To ensure a close match, we used a caliper of one-tenth of the standard deviation of the propensity score (18) . Propensity scores were estimated using Cox regression (16) . The Cox model used contained the following confounders: age, sex, average daily glucocorticoid dose, previous vertebral or nonvertebral fracture, current use of prescription calcium plus vitamin D, and a number of medical conditions (Table 1  and Supplemental Table 2 ). With the exceptions of age and sex, these confounders were time varying. The duration of calcium plus vitamin D use was defined as the time span from the first to the last dispensation plus 90 days. For continuous variables, we assessed linearity by including first-and seconddegree fractional polynomial terms (19) , which were tested using likelihood ratio tests. For time-fixed variables, we assessed the proportional hazards assumption using the score test for correlation of scaled Schoenfeld residuals with ln(time). These correlations were viewed in a scatter plot for continuous variables and log-log plots for binary variables. We did not observe a violation of the proportional hazards assumption.
Outcomes
There were three study outcomes: hip fracture, vertebral fracture, and nonvertebral fracture. For consistency with a previous observational study (20) , the outcome of nonvertebral fracture included fractures of the clavicle, hip, humerus, wrist, pelvis, and leg. Subjects could be a case of more than one outcome, but only the first fracture of each outcome was analyzed.
Fractures were identified using the International Classification of Diseases, 10th Revision diagnosis codes recorded in the National Patient Register (Supplemental Table 2 ). This register does not always distinguish incident fractures from readmissions and follow-up care, so we excluded diagnoses made within 180 days of a similar type of fracture diagnosis (clavicle, hip, humerus, wrist, pelvis, leg, or vertebra) to avoid misclassification. In addition, fracture diagnoses were excluded if an International Classification of Diseases, 10th Revision code indicated that it was made at a follow-up examination for a fracture or another type of orthopedic follow-up care (Supplemental Table 2 ).
Statistical analysis
For alendronate users, baseline was defined as the day following the first dispensation of alendronate. For nonusers, baseline was defined so that the prior duration of glucocorticoid therapy was identical to that of the matched alendronate user. Subjects were followed until death, discontinuation of glucocorticoid therapy, decrease in average glucocorticoid dose to ,2.5 mg/d, or 31 December 2011 (whichever came first). As long as the average dose was $2.5 mg/d, we assumed that therapy was continuous. For nonusers of alendronate, followup also ended if they received a bisphosphonate.
We assessed covariate balance using standardized mean differences. Differences ,0.1 were considered to indicate a close match (18) . Fracture occurrence was measured using incidence rates, but we also provide Kaplan-Meier curves of cumulative incidence. Because the data were matched, these curves were compared using the Akritas test (21) . Hazard ratios were calculated using Cox regression, and confidence intervals were estimated using robust standard errors to take the matching into account (22) . The proportional hazard assumption was not strictly satisfied, but we judged that hazard ratios adequately summarized the data.
We tested for interaction of alendronate use with average daily glucocorticoid dose by applying the Wald test to product terms in Cox models. Average daily glucocorticoid dose was a time-varying variable, and the product terms were modeled nonlinearly using restricted cubic splines. Knots were placed at uniform percentiles, and the necessary number of knots was determined using the Akaike information criterion. The same approach was used to test for interaction of alendronate use with prior duration of glucocorticoid therapy at baseline (a time-fixed variable). In a subgroup analysis, treatment-by-sex product terms were used to test for interaction and to calculate hazard ratios for women and men separately.
The datasets showed some inconsistencies among dates of death, incident fractures, and drug dispensations. In these cases, we let dates of death take precedence. If only the month or year of death was known, we assumed that the date of death was the latest known date of life.
We performed four sensitivity analyses. First, we followed alendronate users until they were dispensed a different bisphosphonate or until 90 days after the final dispensation (if one of these dates came before those previously mentioned). Second, we analyzed injurious falls that did not result in fractures as an outcome because alendronate should not affect the risk of falling (incident fall was defined similar to incident fracture). Third, we redefined incident fracture to include a fracture diagnosis only if there was no previous diagnosis for a similar type of fracture. Fourth, we also redefined incident fracture to include a fracture diagnosis even if it was made within 180 days of a diagnosis for a similar type of fracture.
P values ,0.05 were considered statistically significant. Statistical analyses were performed in Stata, version IC 14 (StataCorp). We did not use a prespecified analysis plan.
Results
Study cohort and follow-up
The study cohort comprised 16,890 alendronate users and 16,890 matched nonusers (Fig. 1) . When comparing alendronate users and nonusers, all baseline characteristics had a standardized mean difference ,0.1 (Table 1) . Overall, subjects had a mean age of 72 years, and 34% were men. The subjects had been taking glucocorticoids for a median of 1.4 months at baseline (interquartile range 0.2 to 6.3 months). By this time, the median average dose was 17.2 mg/d of prednisone (or equivalent) (interquartile range 9.9 to 29.4 mg/d). By the end of follow-up, the median average dose had decreased to 8.6 mg/d (interquartile range 6.1 to 12.6 mg/d).
The median follow-up was 14.5 months (interquartile range 6.4 to 29.4 months). Alendronate users had a longer median follow-up than did nonusers (17.0 vs 12.2 months), but follow-up ended due to initiation of bisphosphonate therapy in 22.5% of nonusers. Other reasons why follow-up ended were discontinuation of glucocorticoid therapy (46.3% users and 38.1% nonusers), end of the study (41.8% users and 27.1% nonusers), death (10.5% users and 10.6% nonusers), and low average glucocorticoid dose (1.4% users and 1.7% nonusers).
By the end of follow-up, 1.8% of alendronate users had switched to a different bisphosphonate. Over the study period (2006 through 2011), the median interval from the final dispensation of alendronate to the end of follow-up was 2.2 months earlier for the dispensation (interquartile range 7.1 to 0.4 months earlier).
Fractures
The incidence rate of nonvertebral fracture was 2.0 cases/100 person-years in alendronate users and 2.4 cases in nonusers (Table 2 and Fig. 2) . This difference corresponded to a 16% lower rate in users (hazard ratio 0.84; 95% confidence interval 0.75 to 0.94). For hip fractures specifically, the rate was 34% lower in alendronate users relative to nonusers (hazard ratio 0.66; 95% confidence interval 0.55 to 0.78); the incidence rate of hip fracture was 0.8 cases/100 person-years in users and 1.2 cases in nonusers. The incidence rate of vertebral fracture was 0.3 cases/100 person-years in users and 0.4 cases in nonusers (hazard ratio 0.80; 95% confidence interval 0.59 to 1.07). For each type of fracture, the association with alendronate use was similar in women and men (Table 2) .
Alendronate use was most strongly associated with a lower rate of nonvertebral fracture in patients who received high doses of glucocorticoid (Fig. 3) . Such a trend was also observed for hip fracture, although it was not significant (P = 0.42). Alendronate use was not associated with a lower rate of nonvertebral fracture in subjects who received alendronate after a few months of glucocorticoid therapy (Fig. 4) .
Sensitivity analyses
We obtained similar results when following alendronate users until they switched to a different bisphosphonate or until 90 days after the final dispensation of alendronate (Supplemental Table 3 ). The incidence rate of injurious fall without fracture was similar in alendronate users and nonusers (2.7 vs 2.6 cases/100 personyears; hazard ratio 1.02; 95% confidence interval 0.92 to 1.13). Moreover, this lack of association was not related to average glucocorticoid dose or prior duration of 
Discussion
This study showed that alendronate use was associated with a 16% lower rate of nonvertebral fracture, including a 34% lower rate of hip fracture, in older adults taking oral glucocorticoids ($2.5 mg/d of prednisone or equivalent for $3 months). For nonvertebral fracture, the association was strongest in patients who received high doses of glucocorticoid.
As this was an observational study, the reported associations were not necessarily causal. However, two meta-analyses showed similar, but not statistically significant, associations when pooling clinical trials of bisphosphonates: among patients taking glucocorticoids, the risks of nonvertebral fracture were 21% and 23% lower in the bisphosphonate groups (10, 11) . One of the meta-analyses also showed a 31% lower risk of hip fracture in the bisphosphonate group, although this estimate was based on only five cases (10) . Because our large observational study showed similar results with alendronate, and because current evidence does not suggest that alendronate differs from most other bisphosphonates in terms of efficacy (23), the associations we report appear to be reasonable estimates of the effect of alendronate during glucocorticoid therapy.
The results of this study are also similar to those of higher-powered meta-analyses that examined the effect of alendronate in postmenopausal women. Three such meta-analyses showed 13% to 16% reductions in nonvertebral fractures (24) (25) (26) . In addition, two of the meta-analyses showed 31% and 37% reductions in hip fractures (24, 26) . Nevertheless, greater effects have also been reported: one meta-analysis showed a 49% reduction in nonvertebral fractures with alendronate $10 mg/d, although this restriction excluded the two largest clinical trials (24) . Another meta-analysis showed a 65% reduction in hip fractures among patients with T-scores #22 (27) . Overall, the results of our study appear to be consistent with equal effectiveness of alendronate in patients treated with glucocorticoids and in postmenopausal women. Equal effectiveness has previously been suggested for these patient groups but not been verified (10, 28) .
Although our results appear consistent with metaanalyses, two previous observational studies of alendronate found stronger associations (20, 29) . In patients taking glucocorticoids, these studies reported 34% and 45% lower risks of nonvertebral fracture with alendronate (20, 29) ; one of the studies also reported a 65% lower risk of hip fracture (29) . Part of these differences could be due to chance variation, but two major differences in study design should be noted. First, we included a control group, whereas Thomas et al. (20) examined the change in alendronate users' fracture risk over time. Although this approach prevented confounding by differences in baseline characteristics, part of the decrease in fracture risk could be unrelated to treatment. For example, fracture risks decrease after a previous fracture (30) , and 11% of the subjects in the study by Thomas et al. (20) had sustained a fracture in the past 6 months. Second, we followed alendronate users from the initiation of alendronate treatment, whereas Axelsson et al. (29) included alendronate users who had been treated for a median of 3 years at baseline. This inclusion probably led to an overestimation of the effect of alendronate, as this effect is gradual (31) .
Our results showed that the association between alendronate use and nonvertebral fracture was strongest in patients who received high doses of glucocorticoid. There are few data on the relative effect of alendronate according to glucocorticoid dose, but two clinical trials showed greater effects on bone mineral density as the glucocorticoid dose increased, a finding that was in part explained by greater bone loss in the placebo groups as the dose increased (32, 33) . Furthermore, Axelsson et al. (29) found stronger associations between alendronate use and a lower risk of nonvertebral fracture in patients who received $7.5 mg/d of prednisolone compared with 5 to 7.5 mg/d, although a test for interaction was not performed. These data suggest that the relative effect of alendronate may be greater at high doses of glucocorticoids.
In this study, alendronate use was not associated with a lower risk of fracture among patients who had been on glucocorticoid therapy for a few months when they received alendronate. In contrast, clinical trials have shown that alendronate has beneficial effects on bone mineral density regardless of prior duration of glucocorticoid therapy (34, 35) . Although these trials did not examine effects on fractures according to duration of therapy, our result may be caused by confounding. Confounding could arise if, for example, alendronate was prescribed to patients who were discovered to have low bone mineral density; less confounding might arise if alendronate were prescribed to prevent a decrease in bone mineral density. Thus, preventive therapy may explain why alendronate use was associated with a lower risk of fracture only among patients who received alendronate during the first months of glucocorticoid therapy.
The main limitation of this study was the risk of confounding by unavailable variables, such as smoking, bone mineral density, and the indication for glucocorticoid therapy. Confounding by these variables would probably mean that the effect of alendronate was underestimated, because alendronate is more likely to be prescribed to patients who are at high risk of fracture. However, cumulative incidence curves were similar for alendronate users and nonusers during the first months of follow-up, suggesting that baseline risks were balanced. Another limitation was the lack of data on diagnoses made in primary care. This limitation means that the prevalence of conditions such as asthma may have been underestimated (36) . In addition, this limitation indicates that the incidence of vertebral fracture was underestimated, because most clinical vertebral fractures are managed in primary care in Sweden (37) . Although such an underestimation is unfortunate, vertebral fracture was not the main outcome of the study. A strength of this study was that we did not restrict analyses to adherent alendronate users. Poor adherence is common in clinical practice and probably reduces the effectiveness of treatment (38) , but the associations we reported apply to the levels of adherence observed in clinical practice.
In sum, this study showed that alendronate use was associated with a lower risk of nonvertebral fracture, including a lower risk of hip fracture. Because metaanalyses have shown similar results (10, 11, (24) (25) (26) , these associations appear to be reasonable estimates of the effect of alendronate in patients taking glucocorticoids. In addition, the similarities with meta-analyses suggest that alendronate does indeed have comparable effects in patients treated with glucocorticoids and in postmenopausal women.
